Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03486821 · ClinicalTrials.gov registry record · NA
Ultra-hypofractionated Radiation in Prostate Cancer
A NA study of Early Stage Prostate Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03486821: Active NA study of Early Stage Prostate Cancer, sponsored by University of Kansas Medical Center.
NCT03486821 is a NA study of Early Stage Prostate Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03486821, a NA study of Early Stage Prostate Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to demonstrate that ultra-hypofractionation of prostate cancer does not increase urinary toxicity as defined by the EPIC-26 GU domain patient reported outcome.
Primary Outcome
Patient reported urinary function, as defined by the EPIC-26 GU domain patient reported outcome for prostate cancer patients
Conditions Studied
Interventions
- RADIATION Hypofractionated Radiation
Study Locations (1)
Kansas
- University of Kansas Medical Center/ Cancer Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2026-03-01 |
| Phase | NA |
What the registry record for NCT03486821 still lists
NCT03486821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Early Stage Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Hypofractionated Radiation is the first listed.
NCT03486821 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03486821 about?
NCT03486821 is a clinical study titled "Ultra-hypofractionated Radiation in Prostate Cancer". The primary objective of this study is to demonstrate that ultra-hypofractionation of prostate cancer does not increase urinary toxicity as defined by the EPIC-26 GU domain patient reported outcome.
What is the current status of trial NCT03486821?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 13 participants. The study started on 2018-03-22. Estimated completion is 2026-03-01.
What conditions does trial NCT03486821 study?
This clinical trial studies the following conditions: Early Stage Prostate Cancer.
What interventions are being tested in trial NCT03486821?
The interventions under investigation include: Hypofractionated Radiation (RADIATION).
Who is sponsoring clinical trial NCT03486821?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03486821 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03486821's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI